Target intelligence / Profile preview

Natural killer cell stress-induced ligands (NKG2DL) (NKG2DL)

Target
NKG2DL
Molecular classification
MHC class I-like proteins, Cell surface glycoproteins
01

Overview

Natural killer cell stress-induced ligands (NKG2DLs) are a group of cell surface proteins, including MHC class I polypeptide-related sequence A (MICA), MICB, and the UL16-binding protein (ULBP) family, that are upregulated on host cells in response to cellular stress, DNA damage, or malignant transformation (PMID: 21739672). These ligands serve as critical recognition signals for the immune system by binding to the activating receptor NKG2D (KLRK1) expressed on Natural Killer (NK) cells and certain T cell subsets (UniProt: P43481, Q29980). Binding triggers the activation of effector cells, leading to the targeted destruction of the stressed or transformed host cell through the release of cytotoxic granules (PMID: 11777960). In many cancers, tumors utilize proteolytic shedding of these ligands (e.g., sMICA) as an immune evasion mechanism to desensitize effector cells and avoid detection (PMID: 12191486). Therapeutic strategies currently in development include NKG2D-based CAR-T cells (e.g., CYAD-01), monoclonal antibodies that stabilize ligand expression or prevent shedding (e.g., 7C6), and bispecific engagers designed to bridge NKG2DL-expressing cells with immune effectors (PMID: 29590616, PMID: 31110293).

Other names
NKG2D ligandsStress-induced ligandsMHC class I polypeptide-related sequence AMHC class I polypeptide-related sequence BMICAMICBUL16-binding proteinsULBPsRAET1 proteins
02

Mechanism of action

Binding to the activating NKG2D receptor on effector lymphocytes to trigger cytotoxic granule release and cytokine production against ligand-expressing cells (PMID: 11777960).

03

Biological functions

Immune responseNK cell activationCell-mediated cytotoxicityT cell costimulationApoptosis induction
04

Disease associations

CancerInfectionAutoimmune diseaseTransplant rejection
05

Safety considerations

On-target off-tumor toxicity due to low-level expression on healthy tissuesImmune evasion via proteolytic ligand sheddingCytokine release syndrome (CRS) in cell-based therapiesTumor microenvironment immunosuppression
06

Interacting drugs

CYAD-01

3 more in the full profile.

07

Biomarkers

MICA surface expressionMICB surface expressionSoluble MICA (sMICA) serum levelsSoluble MICB (sMICB) serum levelsULBP1-6 expression

Beyond the preview

Go deeper on Natural killer cell stress-induced ligands (NKG2DL) (NKG2DL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer cell stress-induced ligands (NKG2DL) (NKG2DL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call